GRAMMY® AWARD-WINNING SINGER JENNIFER HUDSON LENDS HER VOICE TO STAND UP TO CANCER AND GENENTECH IN “TWO WORLDS. ONE DREAM.” CAMPAIGN IN THE FIGHT AGAINST CANCERNew PSA Inspires Everyone to Come Together in the Spirit of Collaboration and to Advance Cancer Research
LOS ANGELES / NEW YORK – July 30, 2014 – Stand Up To Cancer (SU2C), a program of the Entertainment Industry Foundation, and Genentech, one of the world’s leading biotech companies, have joined forces with GRAMMY®-winning singer, Oscar®-winning actress, and SU2C Ambassador Jennifer Hudson for their latest campaign, entitled: “Two Worlds. One Dream.”
Debuting in July, the public service announcement (PSA), which will appear in print, digital, radio, and broadcast media, highlights the incredible work being done by today’s leading cancer researchers and stresses the importance of supporting innovative research.
The powerful PSA, which features Jennifer Hudson and Genentech senior scientist Shiva Malek, Ph.D., notes the similarities between the worlds of art and science—reinforcing how much can be accomplished when we work together. The “Two Worlds. One Dream.” campaign charges everyone—from doctors and scientists to artists to patients and survivors—to unite in the fight against the collection of diseases known as cancer, which take the lives of nearly 1,600 Americans every day.
“I, like many others, have friends and loved ones who have been affected by cancer,” said Jennifer Hudson. “I’m proud to join Genentech and Stand Up To Cancer on this PSA campaign, which showcases cancer researchers as the rock stars they really are and highlights the importance of supporting their vital work.”
“Stand Up To Cancer was built on the idea that people from different disciplines can come together in the hope of making everyone diagnosed with cancer a survivor,” said Lisa Paulsen, co-founder of Stand Up To Cancer. “We are so grateful to Jennifer Hudson and Genentech for their invaluable support. This PSA champions collaboration, which is a cornerstone of SU2C, to inspire the public to realize their role in supporting scientific research that has the ability to transform lives.”
“Stand Up To Cancer brings together some of the best and brightest minds in cancer research to collaborate in the fight against this terrible disease,’’ said Geoff Teeter, Vice President of Corporate Relations at Genentech. ‘’We are excited to partner with Jennifer Hudson and SU2C on this campaign, and share the belief that progress happens faster when we work together.’’
For more information on the campaign, visit standup2cancer.org. To join the conversation, like us on Facebook at @StandUpToCancer or follow us on Twitter at @SU2C.
Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
About Stand Up To Cancer
Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry’s resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about progress being made in the fight against the disease. As SU2C’s scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, Ph.D., conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.
For more information on Stand Up To Cancer visit http://www.standup2cancer.org.
# # #